Your browser doesn't support javascript.
loading
Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.
Bhiman, Jinal N; Richardson, Simone I; Lambson, Bronwen E; Kgagudi, Prudence; Mzindle, Nonkululeko; Kaldine, Haajira; Crowther, Carol; Gray, Glenda; Bekker, Linda-Gail; Shinde, Vivek; Bennett, Chijioke; Glenn, Gregory M; Madhi, Shabir A; Moore, Penny L.
Afiliación
  • Bhiman JN; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Richardson SI; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Lambson BE; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Kgagudi P; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Mzindle N; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Kaldine H; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Crowther C; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Gray G; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Bekker LG; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Shinde V; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Bennett C; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Glenn GM; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
  • Madhi SA; MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • Moore PL; The South African Medical Research Council, Tygerberg, South Africa.
Sci Rep ; 13(1): 1222, 2023 01 21.
Article en En | MEDLINE | ID: mdl-36681693
The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies induced by vaccination with ancestral spike or infection with previously circulating variants. The NVX-CoV2373 vaccine, a protein nanoparticle vaccine containing the ancestral spike sequence, has value in countries with constrained cold-chain requirements. Here we report neutralizing titers following two or three doses of NVX-CoV2373. We show that after two doses, Omicron sub-lineages BA.1 and BA.4/BA.5 were resistant to neutralization by 72% (21/29) and 59% (17/29) of samples respectively. However, after a third dose of NVX-CoV2373, we observed high titers against Omicron BA.1 (GMT: 1,197) and BA.4/BA.5 (GMT: 582), with responses similar in magnitude to those triggered by three doses of an mRNA vaccine. These data are of particular relevance as BA.4/BA.5 is dominating in multiple locations, and highlight the potential utility of the NVX-CoV2373 vaccine as a booster in resource-limited environments.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: Sci Rep Año: 2023 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: Sci Rep Año: 2023 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Reino Unido